Home › Research › Getting a diagnosis
PET imaging of amyloid in Alzheimer's disease
Nordberg A.. The Lancet. Neurology, 2004-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is the most common form of dementia and is characterised by progressive impairment in cognitive function and behaviour. The pathological features of AD include neuritic plaques composed of amyloid-beta peptide (Abeta) fibrils, neurofibrillary tangles of hyperphosphorylated tau, and neurotransmitter deficits. Increases in the concentration of Abeta in the course of the disease with subtle effects on synaptic efficacy will lead to gradual increase in the load of amyloid plaques and progression in cognitive impairment. Direct imaging of amyloid load in patients with AD in vivo would be very useful for the early diagnosis of AD and the development and assessment of new treatment strategies. Three different strategies are being used to develop compounds suitable for in vivo imaging of amyloid deposits in human brains. Monoclonal antibodies against Abeta and peptide fragments have had limited uptake by the brain when tested in patients with AD. When putrescine-gadolinium-Abeta has been injected into transgenic mice overexpressing amyloid, labelling has been observed with MRI. The small molecular approach for amyloid imaging has so far been most successful. The binding of different derivatives of Congo red and thioflavin has been studied in human autopsy brain tissue and in transgenic mice. Two compounds, fluorine-18-labelled-FDDNP and carbon-11-labelled-PIB, both show more binding in the brains of patients with AD than in those of healthy people. Additional compounds will probably be developed that are suitable not only for PET but also for single photon emission CT (SPECT).
What this study adds
Evidence grade: Low
This is a narrative review. This 2004 review surveys three ways researchers were trying to see amyloid plaques in the living brain: antibodies, which had "limited uptake by the brain"; an MRI agent, tested only in mice; and small-molecule tracers, which it calls the most successful approach so far. It reports that two PET tracers, FDDNP and PIB, "show more binding in the brains of patients with AD than in those of healthy people", but gives no accuracy figures.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nordberg, A. (2004). PET imaging of amyloid in Alzheimer's disease. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(04)00853-1
Vancouver
Nordberg A. PET imaging of amyloid in Alzheimer's disease. The Lancet. Neurology. 2004. doi:10.1016/s1474-4422(04)00853-1. PMID: 15324720.
BibTeX
@article{nordberg2004-15324720,
author = {Nordberg, A.},
title = {{PET imaging of amyloid in Alzheimer's disease}},
journal = {The Lancet. Neurology},
year = {2004},
doi = {10.1016/s1474-4422(04)00853-1},
pmid = {15324720},
url = {https://doi.org/10.1016/s1474-4422(04)00853-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- When putrescine-gadolinium-Abeta has been injected into transgenic mice overexpressing amyloid, labelling has been observed with MRI.
- The small molecular approach for amyloid imaging has so far been most successful.
- The binding of different derivatives of Congo red and thioflavin has been studied in human autopsy brain tissue and in transgenic mice.
- Two compounds, fluorine-18-labelled-FDDNP and carbon-11-labelled-PIB, both show more binding in the brains of patients with AD than in those of healthy people.
- Additional compounds will probably be developed that are suitable not only for PET but also for single photon emission CT (SPECT).
Why it matters
This 2004 review surveys three ways researchers were trying to see amyloid plaques in the living brain: antibodies, which had "limited uptake by the brain"; an MRI agent, tested only in mice; and small-molecule tracers, which it calls the most successful approach so far. It reports that two PET tracers, FDDNP and PIB, "show more binding in the brains of patients with AD than in those of healthy people", but gives no accuracy figures. Its case for amyloid imaging is a hoped-for one, early diagnosis and judging new treatments, not a tested diagnostic or treatment result.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Evidence strengthLow
How this study scored 50/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2004 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 466 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 19.4 citations a year over 24 year(s) since 2004 |
| Impact for its field and year | 4 / 6 | Cited 19.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 17 other studies in this library |
| Still being cited | 2 / 4 | Cited 37 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Agneta K. Nordberg: h-index 103 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Karolinska Institutet: institution h-index 1,477 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15324720) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.